Federal contract award
75F40122C00143
DPMWP 217/CDRH-2022-112765 - DEVELOP STANDARDS FOR DATA QUALITY AND DATA SOURCES THAT INCREASE THE QUALITY, INTEROPERABILITY, AND USABILITY OF REAL-WORLD DATA.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $47.2M |
| Current contract value | $47.2M |
| Potential contract value / ceiling | $47.2M |
| Start date | Sep 26, 2022 |
| Current end date | Jun 10, 2026 |
| Potential end date | Jun 10, 2026 |
| Latest award activity | Jun 9, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 11 of 11 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 9, 2026 | P00010 | $96.0K | SYSTEMIC HARMONIZATION AND INTEROPERABILITY ENHANCEMENT FOR LABORATORY DATA (SHI |
| Apr 24, 2026 | P00009 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO JUNE 10, 2026. |
| Mar 26, 2026 | P00008 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO APRIL 26, 2026. |
| Sep 11, 2025 | P00007 | $200.0K | SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE |
| Jul 16, 2025 | P00006 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO MARCH 27, 2026. |
| Dec 23, 2024 | P00005 | $0 | OPTIMIZING KNOWLEDGE MANAGEMENT PROCESSES THAT ENABLE A HIGHLY RELIABLE LABORATORY DATA LIFE CYCLE |
| Jan 26, 2024 | P00004 | $0 | OPTIMIZING KNOWLEDGE MANAGEMENT PROCESSES THAT ENABLE A HIGHLY RELIABLE LABORATORY DATA LIFE CYCLE |
| Dec 29, 2023 | P00003 | $0 | OPTIMIZING KNOWLEDGE MANAGEMENT PROCESSES THAT ENABLE A HIGHLY RELIABLE LABORATORY DATA LIFE CYCLE |
| May 30, 2023 | P00002 | $36.9M | DPMWP 217/CDRH-2022-112765 - AMEND THE CONTRACT TYPE: FIRM FIXED PRICE (FFP) WITH COST REIMBURSABLE (CR) TRAVEL AND OTHER DIRECT COSTS (ODCS), AND PROVIDE A STATEMENT UNDER EACH CONTRACT CLIN TO CLARIFY, THE STATED PRICE IS INCLUSIVE OF CR TRAVEL AND |
| Nov 22, 2022 | P00001 | $0 | DPMWP 217/CDRH-2022-112765 - AMEND THE CONTRACT TYPE: FIRM FIXED PRICE (FFP) WITH COST REIMBURSABLE (CR) TRAVEL AND OTHER DIRECT COSTS (ODCS), AND PROVIDE A STATEMENT UNDER EACH CONTRACT CLIN TO CLARIFY, THE STATED PRICE IS INCLUSIVE OF CR TRAVEL AND |
| Sep 26, 2022 | 0 | $10.0M | DPMWP 217/CDRH-2022-112765 - DEVELOP STANDARDS FOR DATA QUALITY AND DATA SOURCES THAT INCREASE THE QUALITY, INTEROPERABILITY, AND USABILITY OF REAL-WORLD DATA. |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | Jan 28, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Jan 28, 2021 |
| Benjamin Golway | Contact | Benjamin.Golway@fda.hhs.gov 3018374464 | Source | Nov 20, 2020 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Nov 20, 2020 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.